Screening for hepatocellular carcinoma
Abstract
Introduction and purpose of the work. Hepatocellular carcinoma (HCC) is one of the most common malignant tumours all over the world. It is considered to be the sixth malignant tumour in terms of incidence. It is also characterized by high mortality rate, which, depending on the geographic region, gives the second or third place on the list of cancer related death. There are many known risk factors for the development of hepatocellular carcinoma, the most important of which is liver cirrhosis. Thus the cirrhotic patients are generally accepted for screening. Actually it is recommended to perform abdominal ultrasound every 6 months in this group. Other forms of screening are also tested.
Description of the current knowledge and conclusions.
Literature review provides indisputable evidences for the need of screening for liver cancer. Doubts remain only about the appropriateness of widening the screening group and possibly extending the scope of diagnostic tools.
The authors, by analyzing the available knowledge for hepatocellular carcinoma screening, consider the qualification of actually recommended screening tests to be insufficient in countries with high incidence. Relatively high incidence of HCC, even greater mortality in the context of all cancers, safety, low cost and universal access to ultrasound, should, in the opinion of the authors, be enough for the consideration to widen the screening guidelines in countries with high incidence of HCC. In countries with low incidence, e.g. in Poland, the screening in healthy population do not belong to the priority.
Full Text:
PDFReferences
Dimitroulis D, Damaskos C, Valsami S, Davakis S, Garmpis N, Spartalis E, et al.. From diagnosis to treatment of hepatocellular carcinoma: An epidemic problem for both developed and developing world. World J Gastroenterol. 2017; 7; 23 (29): 5282-5294.
Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic
management of hepatocellular carcinoma. World J Gastroenterol. 2015; 14; 21 (42): 12003-12021.
Limaiem F, Bouhamed M, Sahraoui G, Mzabi S. Hepatocellular carcinoma: a
clinicopathological study of 64 cases. Pan Afr Med J. 2017; 16; 27:41.
Schuppan D, Afdhal NH. Liver cirrhosis. Lancet. 2008; 8; 371 (9615): 838-851.
Massarweh NN, El-Serag HB. Epidemiology of Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma. Cancer Control. 2017; 24 (3): 1073274817729245. doi: 10.1177/1073274817729245.
Chen S, Duan W, You H, Jia J. A brief review on prognostic models of primary
biliary cholangitis. Hepatol Int. 2017; 14. doi: 10.1007/s12072-017-9819-9.
Singh S., Talwalkar J.A. Primary sclerosing cholangitis: Diagnosis, prognosis, and management. Clin. Gastroenterol. Hepatol. 2013; 11:898–907. doi: 10.1016/j.cgh.2013.02.016.
Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J
Gastroenterol. 2014; 21; 20 (23):7312-7324.
Naschitz JE, Slobodin G, Lewis RJ, Zuckerman E, Yeshurun D. Heart diseases
affecting the liver and liver diseases affecting the heart. Am Heart J. 2000; 140 (1): 111-120.
Keng VW, Largaespada DA, Villanueva A. Why men are at higher risk for
hepatocellular carcinoma? J Hepatol. 2012; 57 (2): 453-454.
Kumar M, Kumar R, Hissar SS, Saraswat MK, Sharma BC, Sakhuja P, Sarin SK. Risk
factors analysis for hepatocellular carcinoma in patients with and without
cirrhosis: a case-control study of 213 hepatocellular carcinoma patients from
India. J Gastroenterol Hepatol. 2007; 22 (7): 1104-1111.
Fattovich G, Stroffolini T, Zagni I, Donato F. Hepatocellular carcinoma in
cirrhosis: incidence and risk factors. Gastroenterology. 2004; 127 (5 Suppl.
: S35-50.
Fateen W, Ryder SD. Screening for hepatocellular carcinoma: patient selection
and perspectives. J Hepatocell Carcinoma. 2017; 17; 4: 71-79.
Kuo MJ, Chen HH, Chen CL, Fann JC, Chen SL, Chiu SY, et al. Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening. World J Gastroenterol. 2016; 28; 22 (12):m 3460-3670.
Ungtrakul T, Mahidol C, Chun-On P, Laohapand C, Siripongsakun S,
Worakitsitisatorn A, et al. Hepatocellular carcinoma screening and surveillance in 2293 chronic hepatitis B patients in an endemic area. World J Gastroenterol. 2016; 14; 22 (34): 7806-12.
Singal A, Conjeevaram H, Volk N, Fu S, Fontana R, Askari F, et al. Effectiveness of Hepatocellular Carcinoma Surveillance in Patients with Cirrhosis. Cancer Epidemiol Biomarkers Prev. 2012; OF1-7. DOI: 10.1158/1055-9965.EPI-11-1005.
Blehar DJ, Barton B, Gaspari RJ. Learning curves in emergency ultrasound
education. Acad Emerg Med. 2015; 22 (5): 574-582.
Andoulo F A, Noah DN, Djapa R, Kowo M, Talla P, Medjo EH et al. Epidemiology of hepatitis C: related hepatocellular carcinoma in Cameroon. Pan Afr Med J. 2014; 15; 19:379. doi: 10.11604/pamj.2014.19.379.4143.
Bellissimo F, Pinzone MR, Cacopardo B, Nunnari G. Diagnostic and therapeutic
management of hepatocellular carcinoma. World J Gastroenterol. 2015;
; 21 (42): 12003-21. doi: 10.3748/wjg.v21.i42.12003.
El-Serag HB, Davila JA. Surveillance for hepatocellular carcinoma: in whom and
how? Therap Adv Gastroenterol. 2011; 4 (1): 5-10.
Park JH, Park MS, Lee SJ, Jeong WK, Lee JY, Park MJ, et al. Contrast-enhanced US with Perfluorobutane (Sonazoid) used as a surveillance test for Hepatocellular Carcinoma (HCC) in Cirrhosis (SCAN): an exploratory cross-sectional study for a diagnostic trial. BMC Cancer. 2017; 18; 17 (1): 279. doi: 10.1186/s12885-017-3267-8.
Kudo M. Defect Reperfusion Imaging with Sonazoid®: A Breakthrough in
Hepatocellular Carcinoma. Liver Cancer. 2016; 5 (1): 1-7.
Singh GK, Jemal A. Socioeconomic and Racial/Ethnic Disparities in Cancer
Mortality, Incidence, and Survival in the United States, 1950-2014: Over Six
Decades of Changing Patterns and Widening Inequalities. J Environ Public Health.
; 2017: 2819372. doi: 10.1155/2017/2819372.
Singh GK, Siahpush M, Altekruse SF. Time trends in liver cancer mortality,
incidence, and risk factors by unemployment level and race/ethnicity, United
States, 1969-2011. J Community Health. 2013; 38 (5): 926-940.
Jemal A, Ward EM, Johnson CJ, Cronin KA, Ma J, Ryerson B, et al. Annual Report to the Nation on the Status of Cancer, 1975-2014, Featuring Survival. J Natl Cancer Inst. 2017; 1; 109 (9). doi: 10.1093/jnci/djx030.
Yuen MF, Tanaka Y, Fong DY, Fung J, Wong DK, Yuen JC, et al. Independent risk factors and predictive score for the development of hepatocellular carcinoma in chronic hepatitis B. J Hepatol. 2009; 50 (1): 80-88.
Wong VW, Chan SL, Mo F, Chan TC, Loong HH, Wong GL, et al. Clinical scoring system to predict hepatocellular carcinoma in chronic hepatitis B carriers. J Clin Oncol. 2010, 1; 28 (10): 1660-1665.
Ganne-Carrié N, Layese R, Bourcier V, Cagnot C, Marcellin P, Guyader D, et al. ANRS CO12 CirVir Study Group. Nomogram for individualized prediction of hepatocellular carcinoma occurrence in hepatitis C virus cirrhosis (ANRS CO12 CirVir). Hepatology. 2016; 64 (4): 1136-1147.
Conti F, Buonfiglioli F, Scuteri A, Crespi C, Bolondi L, Caraceni P, et al. Early occurrence and recurrence of hepatocellular carcinoma in HCV-related cirrhosis treated with
direct-acting antivirals. J Hepatol. 2016; 65 (4): 727-733.
Kozbial K, Moser S, Schwarzer R, Laferl H, Al-Zoairy R, Stauber R,
Stättermayer AF, et al. Unexpected high incidence of hepatocellular carcinoma in cirrhotic patients with sustained virologic response following interferon-free direct-acting antiviral treatment. J Hepatol. 2016; 65 (4): 856-858.
Cardoso H, Vale AM, Rodrigues S, Gonçalves R, Albuquerque A, Pereira P et al. High incidence of hepatocellular carcinoma following successful interferon-free antiviral therapy
for hepatitis C associated cirrhosis. J Hepatol. 2016; 65 (5): 1070-1071.
Walker M, El-Serag HB, Sada Y, Mittal S, Ying J, Duan Z, et al. Cirrhosis is under-recognised in patients subsequently diagnosed with hepatocellular cancer. Aliment Pharmacol Ther. 2016; 43 (5): 621-30.
Singal AG, Yopp A, S Skinner C, Packer M, Lee WM, Tiro JA. Utilization of
hepatocellular carcinoma surveillance among American patients: a systematic
review. J Gen Intern Med. 2012; 27 (7): 861-867.
Zoller H, Tilg H. Nonalcoholic fatty liver disease and hepatocellular carcinoma. Metabolism. 2016; 65 (8): 1151-1160.
Krgyrou C, Moris D, Vernadakis S. Hepatocellular carcinoma development in
non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. Is it going to be the "Plague" of the 21st century? A literature review focusing on pathogenesis, prevention and treatment. J BUON. 2017; 22 (1): 6-20.
Charrez B, Qiao L, Hebbard L. Hepatocellular carcinoma and non-alcoholic
steatohepatitis: The state of play. World J Gastroenterol. 2016; 28; 22(8): 2494-2502.
Krzakowski M, Zieniewicz K, Habior A, Horban A, Olszewski W, Cianciara J, et al. Rak wątrobowokomórkowy — rozpoznanie i leczenie. Onkol. Prak. Klin. 2009; 5, 4: 125–140.
Pan J, Xin L, Ma YF, Hu LH, Li ZS. Colonoscopy Reduces Colorectal Cancer
Incidence and Mortality in Patients With Non-Malignant Findings: A Meta-Analysis.
Am J Gastroenterol. 2016; 111 (3): 355-465.
Świątkowski M, Meder A, Sobczyński L, Koza J, Szamocka M, Brudny J, Korenkiewicz J. Adenomas detected during screening colonoscopies in the years 2000-2009. Przegl. Gastroenterol. 2012 : Vol. 7, nr 5, s. 299-305.
Świątkowski M, Meder A, Sobczyński L, Koza J, Szamocka M, Brudny J. The screening program for the early colorectal cancer detection performed at the Gastroenterology Department of Nicolaus Copernicus University in Toruń Collegium Medicum in Bydgoszcz in 2000-2009. Gastroenterol. Pol. 2010: 17, 6: 410-415.
DOI: http://dx.doi.org/10.5281/zenodo.1045341
Refbacks
- There are currently no refbacks.
Copyright (c) 2017 © The Author(s)

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Journal of Education, Health and Sport formerly Journal of Health Sciences
Declaration on the original version.
Editors indicates that the main version of the magazine is to issue a "electronic".
The journal has had 5 points in Ministry of Science and Higher Education parametric evaluation. § 8. 2) and § 12. 1. 2) 22.02.2019.
1223 Journal of Education, Health and Sport eISSN 2391-8306 7
ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X
Archives 2011 - 2014
PBN 2011 - 2014
https://pbn.nauka.gov.pl/sedno-webapp/search?search&searchCategory=WORK&filter.inJournal=36616
POL-index 2011 - 2014
https://pbn.nauka.gov.pl/polindex-webapp/browse/journal/journal-32a319c5-a850-4f44-ba70-1418a6087655
BASE 2011 - 2014
http://elibrary.ru/contents.asp?titleid=37467
http://journal.rsw.edu.pl/index.php/JHS/issue/archive
Indexed in Bases, Bazy indeksacyjne: ERIH Plus, Worldcat, PBN/POL-Index, ICI Journals Master List, Directory of Open Access Journals (DOAJ), ZBD, Ulrich's periodicals, Google Scholar, Polska Bibliografia Lekarska
US NLM = 101679844
101679844 - NLM Catalog Result - NCBI
https://www.ncbi.nlm.nih.gov/nlmcatalog/101679844
Find a library that holds this journal: http://worldcat.org/issn/23918306
Journal Language(s): English
PBN Poland
https://pbn.nauka.gov.pl/sedno-webapp/journals/49068
POL-index
https://pbn.nauka.gov.pl/polindex-webapp/browse/journal/journal-c39c8169-88d2-45db-9e7f-d948ce9981c4
BASE
Redaction, Publisher and Editorial Office
Instytut Kultury Fizycznej Uniwersytet Kazimierza Wielkiego w Bydgoszczy, Institute of Physical Education Kazimierz Wielki University in Bydgoszcz, Poland 85-091 Bydgoszcz ul. Sportowa 2 www.ukw.edu.pl Copyright by Instytut Kultury Fizycznej UKW w Bydgoszczy http://ojs.ukw.edu.pl/index.php/johs Open Access ISSN 2391-8306 formerly ISSN: 1429-9623 / 2300-665X
The journal has been approved for inclusion in ERIH PLUS.
The ERIH PLUS listing of the journal is available at https://dbh.nsd.uib.no/publiseringskanaler/erihplus/periodical/info?id=485984
SIC Science citation index (calculated on the basis of TCI and Page Rank) 0
Russian Impact factor 0.16
Indexed in Index Copernicus Journals Master List.
http://journals.indexcopernicus.com/Journal+of+Education+Health+and+Sport,p24782242,3.html
ICV 2018 = 95.95 ICV 2017 = 91.30 ICV 2016 = 84.69 ICV 2015 = 93.34 ICV 2014 = 89.51 Standardized Value: 8.27 ICV 2013: 7.32 ICV 2012: 6.41 ICV 2011: 5.48
The InfoBase Index IBI Factor for the year 2015 is 3.56 in InfoBase Index.com.
Website: www.infobaseindex.com
Universal Impact Factor 1.78 for year 2012. (http://www.uifactor.org/AppliedJournals.aspx)
Indexed in Polish Scholarly Bibliography (PBN) (PBN Polska Bibliografia Naukowa) (https://pbn.nauka.gov.pl/journals/36616)
is a portal of the Polish Ministry of Science and Higher Education, collecting information on publications of Polish scientists and on Polish and foreign scholarly journals. Polish Scholarly Bibliograhpy is a part of POL-on - System of Information on Higher Education. It is operated by the Interdisciplinary Centre for Mathematical and Computational Modelling, University of Warsaw.
Indexed in Russian Sciences Index Российский индекс научного цитирования (РИНЦ) http://elibrary.ru/contents.asp?titleid=37467
Indexed in Arianta Polish scientific and professional electronic journals Aneta Drabek i Arkadiusz Pulikowski
(http://www1.bg.us.edu.pl/bazy/czasopisma/czasop_full.asp?id=3595)